CLAIM #34085 · Johnson & Johnson (JNJ) · 2025Q3 earnings call · Oct 14, 2025 · due Dec 31, 2030
“We are increasingly confident in Carvicti's $5 billion peak year sales potential.”
Joaquin Duato · CEO
PENDING
graded after results covering Dec 31, 2030 are reported
How to check this claim
Look at: Carvicti (ciltacabtagene autoleucel) annual global sales, as reported by J&J
It came true if: Annual Carvicti sales reach or exceed $5 billion in a fiscal year
Where: J&J quarterly/annual earnings reports (Innovative Medicine segment product revenue disclosures)
Verify independently
SEC filings for JNJ ↗ · Claim quote is verbatim from the 2025Q3 earnings call.